Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection

被引:20
作者
Felts, AG
Grainger, DW
Slunt, JB
机构
[1] Anthony G Gristina Inst Biomed Res, Herndon, VA USA
[2] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA
[3] GAMMA A Technol Inc, Herndon, VA USA
来源
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE | 2000年 / 49卷 / 05期
关键词
D O I
10.1097/00005373-200011000-00014
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Nosocomially derived gram-negative infections, particularly from antibiotic-resistant pathogens, are a cause of morbidity in patients with severe burn wounds. Methods: Locally delivered polyclonal antibodies and systemically infused ceftazidime were combined in a lethal murine burn wound model against a virulent Pseudomonas aeruginosa strain that exhibits intermediate resistance to ceftazidime, Results: Survival was synergistically enhanced in cohorts treated both locally (subeschar) with pooled polyclonal human immunoglobulin G (l-mg dose) and intravenously with infused ceftazidine (0.44 mg dose). Enhancement of survival correlated with reduced bacterial quantitation in local and systemic tissue observed in separate burned cohorts, Burned, infected mice treated prophylactically with either individual treatment at the same dose or a combination of both treatments administered systemically showed no survival enhancement as compared with the untreated control group, Conclusion: Treatment of antibiotic-resistant burn wound infections with antibiotics together with locally delivered immunoglobulins may improve antibiotic protective effects against antibiotic-resistant pathogens.
引用
收藏
页码:873 / 878
页数:6
相关论文
共 30 条
[1]   Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model [J].
Barekzi, NA ;
Poelstra, KA ;
Felts, AG ;
Rojas, IA ;
Slunt, JB ;
Grainger, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1609-1615
[2]  
BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207
[3]   RETURN TO THE PAST - THE CASE FOR ANTIBODY-BASED THERAPIES IN INFECTIOUS-DISEASES [J].
CASADEVALL, A ;
SCHARFF, MD .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (01) :150-161
[4]  
COMETTA A, 1994, CLIN EXP IMMUNOL, V97, P69
[5]   Methicillin-resistant Staphylococcus aureus versus the burn patient [J].
Cook, N .
BURNS, 1998, 24 (02) :91-98
[6]  
Cross AS, 1995, ADV EXP MED BIOL, V383, P123
[8]   Laboratory mutants of OXA-10 β-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa [J].
Danel, F ;
Hall, LMC ;
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (03) :339-344
[9]  
DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79
[10]  
DWYER JM, 1992, NEW ENGL J MED, V326, P107